CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
and Tolerability of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney...
Phase 3
Berlin, Germany and 319 other locations
to evaluate efficacy, safety and tolerability of treatment with zibotentan/dapagliflozin and dapagliflozin alone in participants with chronic kidney...
Phase 3
Berlin, Germany and 295 other locations
receptor is known to trigger injury and inflammation in the kidney and is therefore thought to play a role in CKD.Empagliflozin lowers blood...
Phase 2
Berlin, Germany and 189 other locations
Researchers are looking for a better way to treat children who have chronic kidney disease (CKD), which is long-term kidney...
Phase 3
Berlin, Germany and 145 other locations
Researchers are looking for a better way to treat children who have chronic kidney disease (CKD), which is long-term kidney...
Phase 3
Berlin, Germany and 143 other locations
performed thus far excluded patients with an eGFR below 25 mL/min/1.73m2 at inclusion, prevalent dialysis patients, and kidney transplant r...
Phase 3
Berlin, Germany and 64 other locations
of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/ ...
Phase 3
Berlin, Germany and 749 other locations
(for example heart attack and stroke) in people with cardiovascular disease, chronic kidney disease and inflammation.Parti...
Phase 3
Berlin, Germany and 950 other locations
The purpose of this study is to measure the efficacy and safety of baxdrostat/dapagliflozin in participants ≥ 18 years of age with CKD and HTN. This...
Phase 3
Berlin, Germany and 601 other locations
This study will look at how well a drug that reduced the amount of oxalate in the body works in patients that have kidney disease a ...
Phase 2
Berlin, Germany
Clinical trials
Research sites
Resources
Legal